fludarabine has been researched along with Fever of Unknown Origin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Arena, G; Di Renzo, N; Iodice, G; Pizza, V; Tartarone, A; Vigliotti, ML; Volpe, G | 1 |
| Andreeff, M; Beran, M; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Plunkett, W; Robertson, LE | 1 |
2 other study(ies) available for fludarabine and Fever of Unknown Origin
| Article | Year |
|---|---|
Guillain-Barré syndrome complicating mobilization therapy in a case of B-cell chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Fever of Unknown Origin; Filgrastim; Granulocyte Colony-Stimulating Factor; Guillain-Barre Syndrome; Hematopoietic Stem Cell Mobilization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous; Vidarabine | 2004 |
A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Bacteremia; Drug Administration Schedule; Female; Fever of Unknown Origin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pneumonia; Remission Induction; Survival Rate; Vidarabine | 1995 |